疏血通与低分子肝素钙联合治疗急性脑梗死临床观察

Clinical observation on treating acute cerebral infarction by Shuxuetong plus low molecular weight heparin calcium

目的：探讨疏血通联合低分子肝素钙治疗急性进展性脑梗死的临床疗效及安全性。方法：随机将64例急性进展性脑梗死患者分为治疗组（34例）与对照组（30例），其中治疗组给予疏血通联合低分子肝素钙治疗，对照组给予灯盏花素治疗。分别对患者治疗前后神经功能缺损评分、临床疗效及各主要实验室指标进行对比分析。结果：治疗组与对照组患春经治疗后神经功能缺损评分均明显降低，且治疗组下降水平显著优于对照组（P〈0．01或P〈0．05）；治疗组总显效率与总有效率分别为73．53％和91．18％，均显著高于对照组23．33％的总显效率与56．67％的总有效率，两组间差异具有统计学意义（P〈0．01）；两组患者均未出现明显不良反应及凝血功能改变。结论：疏血通联合低分子肝素钙治疗急性进展性脑梗死为一种安全有效的治疗方法，值得进一步推广。

Objective： To investigate clinical effects and security of treating acute cerebral infarction by Shuxue Tong plus low molecular weight heparin calcium. Methods： Randomly divide 64 patients with acute cerebral infarction into treatment group （34 cases） and control group （30 cases）, taking Shuxue Tong plus low molecular weight heparin calcium therapy in treatment group, taking breviscapine therapy in control group. Respectively analyze and compare of neurological deficit score, clinical effect and the main laboratory parameters on patient treatment. Result： Decreased levels in treatment group is better than control group （P〈0.01 or P〈0.05）; the total significant efficiency rate for 73.53% and total efficiency rate for 91.18% in treatment group, is better than the total significant efficiency for 23.33% and total efficiency rate for 56.67% in control group, difference have statistically mean in two group （P〈0.01）; Haven＇t appear the change of adverse reactions and coagulation function in two group patient. Conclusion： Treating acute cerebral infarction by Shuxue Tong plus low molecular weight heparin calcium is a treatment method of effects, is worth being promotion.